Kingfisher International Inc.
  • Home
  • About KFI
    • Approvals
    • Careers
  • Services
    • Safety + Efficacy Studies
    • Bioequivalence and Pharmacokinetic Studies
    • Quality Assurance
    • Clinical Pathology Laboratory
    • Statistics
  • News/Events
  • Contact Uscontact us button
Select Page

KFI is pleased to announce the addition of Dr. Sabina Romanescu and Renu Jeyapala to our Study Director/Investigator team.

Dr. Sabina Romanescu (BScH, DVM, MSc) graduated from the Ontario Veterinary College in 2017. Prior to joining KFI, Dr. Romanescu worked as an associate veterinarian in private practice where she cared for companion animals. In addition to her veterinary training, Dr....

KFI is excited to announce the acquisition of an additional 5,000 sq feet of space as of September 1, 2020.

Construction on new state-of-the art canine and feline housing, enrichment, and procedure space will begin this fall. “Our focus remains to deliver high quality and compassionate science to help change and improve the lives of companion animals” said Dr. Niemuller....

KFI carries out the bioequivalence work for FDA approved Enrofloxacin Flavored Tablets for dogs and cats.

FDA’s Center for Veterinary Medicine approved Felix Pharmaceuticals Pvt. Ltd.’s ANADA for Enrofloxacin Flavored Tablets on May 21, 2020. The flavored tablets provide veterinarians with a new treatment option for disease associated with bacteria susceptible to...

Kingfisher International is pleased to announce the role of Test Facility Management (formerly held by Dr. Cheryl Niemuller) will now be held by Dr. Karrie Young.

As TFM, Dr. Young will be responsible for providing an optimal environment for GLP/GCP compliance at our facilities and for oversight of both GLP/GCP studies and non-GLP/GCP studies conducted at KFI. Dr. Young has been with Kingfisher since 2013 as a facility...
Next Entries »

Recent Posts

  • Introducing KFI’s newest Study Director Zahid Nasir PhD, MBA.
  • KFI is delighted to announce the approval of Carprofen and Deracoxib Chewable tablets by the FDA’s Center for Veterinary Medicine for Felix Pharmaceuticals Pvt. Ltd.
  • KFI Construction Announcement
  • KFI is pleased to introduce our newest Study Director, Dr. Sarah Wright to the Study Director/Investigator team.
  • KFI conducts feline Target Animal Safety study for Solensia® (frunevetmab).

Recent Comments

    KingFisher_logo
    

    (+1) 905.642.3712

    

    info@kingfisherint.com

    • Follow
    GAP_logo

    Copyright © Kingfisher International Incorporated.

    Terms of Use Policy

    Privacy Policy

    Designed by Allegra – Marketing – Print – Design